Importantly, as CAR T cell-derived exosomes do not express PD1, and thereby their anti-tumor impact cannot be abrogated by PD-L1 in TME, using CAR T cell derived exosome has become an innovative therapeutic plans to potentiate therapeutic merits of this therapeutic modality. The gene discussed is PDCD1; the disease is neoplasm.